PO.ET09.06 · 实验与分子治疗
苯并吡喃衍生物的合成与抗癌筛选
Synthesis and anti-cancer screening of benzopyran derivatives
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:全球癌症发病率持续上升,2025 年估计报告有 2000 万新发病例和 1000 万死亡病例。尽管在早期检测和治疗策略方面取得了重大进展,癌症仍是全球主要死亡原因之一。当前的研究努力旨在发现和开发能以最小副作用提供更强抗癌疗效的新型化合物。
研究目的:本研究旨在合成并表征一系列新型 2-(甲苯磺酰氨基)-3-氰基-7,7-二甲基-4-取代苯基-5,6,7,8-四氢苯并吡喃-5-酮衍生物,并评价它们对 MCF-7 乳腺癌细胞的抗癌潜力。采用 MTT 法评估细胞毒活性以测定 IC₅₀ 值,目的是鉴定出一种强效先导化合物,用于开发有效的乳腺癌疗法。
实验步骤:取代苯甲醛与丙二腈在乙醇中以氢氧化钠催化缩合,生成亚芳基-丙二腈中间体,随后与二甲酮回流反应生成环化的苯并吡喃化合物,再在三乙胺存在下用芳基磺酰氯处理,得到最终的苯并吡喃衍生物。该反应序列经由 Knoevenagel 缩合,随后进行 Michael 加成机制。
光谱表征:合成的化合物(THBP2 至 THBP8)通过熔点、UV、IR、¹H NMR 和质谱进行表征。所得光谱数据与所提出的分子结构高度吻合,证实了目标化合物的成功合成和纯度。MCF-7 细胞系中的 MTT 实验:使用 MTT 法在 6.25-100 μg/ml 浓度范围内评价 THBP2 至 THBP8 对 MCF-7 乳腺癌细胞的细胞毒活性。通过 MTT 还原为甲臜来测定细胞存活率,并由剂量反应曲线计算 IC₅₀ 值。
研究结果:成功合成了一系列苯并吡喃衍生物并使用光谱技术进行了表征。MTT 实验结果表明,THBP-6 表现出最高的细胞毒活性,IC₅₀ 值为 20.99 μg/mL,凸显了其作为有前景抗癌先导化合物的潜力。THBP6 尽管含有给电子基团却表现出较低的 IC₅₀,这可能归因于其增强的亲脂性以及促进其与 MCF-7 细胞中靶点更强结合的最佳电子或空间因素。
结论:合成了五种新型苯并吡喃衍生物并筛选了其对 MCF-7 细胞的抗癌活性。在未来展望中,THBP-6 的强效活性提示磺酰胺和氰基取代的苯并吡喃骨架可作为有前景的候选物进一步优化并探索用于抗癌药物开发。
查看英文原文 English abstract
Introduction: Global cancer incidence continues to rise, with an estimated 20 million new cases and 10 million deaths reported in 2025. Despite significant advances in early detection and therapeutic strategies, cancer remains one of the leading causes of mortality worldwide. Current research efforts are directed toward the discovery and development of novel compounds that offer enhanced anticancer efficacy with minimal side effects.
Objectives of the Study: This study aims to synthesize and characterize a series of novel 2-(toluene sulfonamido)-3-cyano-7,7-dimethyl-4-substituted phenyl-5,6,7,8-tetrahydrobenzopyran-5-one derivatives and evaluate their anticancer potential against MCF-7 breast cancer cells. Cytotoxic activity is assessed using the MTT assay to determine IC₅₀ values, with the objective of identifying a potent lead compound for the development of an effective breast cancer therapy.
Experimental Procedure: Substituted benzaldehyde and malononitrile were condensed in ethanol using sodium hydroxide to afford the arylidene-malononitrile intermediate which was subsequently refluxed with dimedone to yield the cyclized benzopyran compound, which was then treated with aryl sulfonyl chloride in the presence of triethylamine to furnish the final benzopyran derivatives. The reaction sequence proceeds through a Knoevenagel condensation followed by a Michael addition mechanism.
Spectroscopic Characterization: The synthesized compounds (THBP2 to THBP8) were characterized by melting point, UV, IR, ¹H NMR, and mass spectrometry. The spectral data obtained were in good agreement with the proposed molecular structures, confirming the successful synthesis and purity of the target compounds. MTT assay in MCF-7 cell line The cytotoxic activity of THBP2 to THBP8 was evaluated against MCF-7 breast cancer cells using the MTT assay at concentrations ranging from 6.25-100 µg/ml. Cell viability was determined from the reduction of MTT to formazan, and IC₅₀ values were calculated from the dose response curves.
Research Outcome: A series of benzopyran derivatives were successfully synthesized and characterized using spectroscopic techniques. The MTT assay results demonstrated that THBP-6 exhibited the highest cytotoxic activity, with an IC₅₀ value of 20.99 µg/mL, highlighting its potential as a promising anticancer lead compound. THBP6 exhibits low IC₅₀ despite containing electron-donating groups, likely due to enhanced lipophilicity and optimal electronic or steric factors that promote stronger binding to the target in MCF-7 cells.
Conclusion: Five novel benzopyran derivatives were synthesized and screened for anticancer activity against MCF-7 cells. In future perspectives, the potent activity of THBP-6 suggests that sulphonamide and cyano substituted benzopyran scaffolds could be further optimized and explored as promising candidates for anticancer drug development.
利益披露 Disclosure
R. Shaika, None..
B. Sharma, None..
M. Gurusamy, None.